

124. (Previously Presented) A compound according to claim 123, wherein R^N is independently unsubstituted aliphatic C_{1-7} alkyl.

125. (Previously Presented) A compound according to claim 123, wherein R^N is independently unsubstituted aliphatic C_{1-4} alkyl.

126. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Me, -Et, -nPr, -iPr, -allyl, -nBu, -sBu, -iBu, or -tBu.

127. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Me or -Et.

128. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Me.

129. (Previously Presented) A compound according to claim 123, wherein each of X^1 and X^2 is independently -I.

130. (Previously Presented) A compound according to claim 123, wherein each of X^1 and X^2 is independently -Br.

131. (Previously Presented) A compound according to claim 123, wherein each of X^1 and X^2 is independently -Cl.

132. (Previously Presented) A compound according to claim 123, wherein R^N is independently C_{1-4} alkyl; and, each X is independently -Cl, -Br or -I.

133. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Me; and, each X is independently -Cl, -Br or -I.

134. (Previously Presented) A compound according to claim 123, wherein R^N is independently C_{1-4} alkyl; and, each X is independently -I.

135. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Et or -Me; and, each X is independently -I.

136. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Me; and, each X is independently -I.

137. (Previously Presented) A compound according to claim 123, wherein the group $-N(CH_2CH_2X^1)(CH_2CH_2X^2)$ is independently attached at the 4-position.

138. (Previously Presented) A compound according to claim 123, wherein R^N is independently C_{1-4} alkyl;
each X is independently -Cl, -Br or -I; and,
the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

139. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Me;
each X is independently -Cl, -Br or -I; and,
the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

140. (Previously Presented) A compound according to claim 123, wherein R^N is independently C_{1-4} alkyl;
each X is independently -I; and,
the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

141. (Previously Presented) A compound according to claim 123, wherein R^N is independently -Et or -Me;
each X is independently -I; and,
the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

142. (Previously Presented) A compound according to claim 123, wherein

R^N is independently -Me;

each X is independently -I; and,

the group $-N(CH_2CH_2X)_2$ is independently attached at the 4-position.

143. (Previously Presented) A compound according to claim 123, wherein n is 0, 1, or 2.

144. (Previously Presented) A compound according to claim 138, wherein n is 0.

145. (Previously Presented) A compound according to claim 123, wherein each R^P , if present, is independently halo, C_{1-4} alkyl, nitro, or cyano.

146. (Previously Presented) A compound according to claim 123, wherein each R^P , if present, is independently:

-F, -Cl, -Br, -I, -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu, -NO₂, or -CN.

147. (Previously Presented) A compound according to claim 123, wherein each R^P , if present, is independently -F, -Cl, -Br, or -I.

148. (Previously Presented) A compound according to claim 123, wherein m is 0, 1, or 2.

149. (Previously Presented) A compound according to claim 138, wherein m is 0.

150. (Previously Presented) A compound according to claim 144, wherein m is 0.

151. (Previously Presented) A compound according to claim 123, wherein each R^M , if present, is independently selected from: C_{1-4} alkyl; C_{1-4} alkoxy; amino; halo; C_{1-4} alkylthio; acyl; ester; amido; cyano; nitro; and, C_{5-6} aryl.

152. (Previously Presented) A compound according to claim 123, wherein each R^M , if present, is independently selected from:

-Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu;

-CF₃, -CH₂F, -CH₂CF₃, -CH₂CH₂F; -CF₂CF₃;

-OMe, -OEt, -O-nPr, -O-iPr, -O-nBu, -O-sBu, -O-iBu, -O-tBu;

-OCF₃, -OCH₂F, -OCH₂CF₃, -OCH₂CH₂F; -OCF₂CF₃;

-NH₂, -NMe₂, -NEt₂, -N(nPr)₂, -N(iPr)₂,

-F, -Cl, -Br, -I;

-SMe, -SEt;

-C(=O)Me;

-C(=O)OMe, -C(=O)OEt;

-CONH₂, -CONHMe;

-CN;

-NO₂; and,

-Ph.

153. (Previously Presented) A compound according to claim 123, wherein each R^M , if present, is independently selected from:

-Me, -Et, -CF₃, -OMe, -OEt, -NH₂, and -NMe₂.

154. (Previously Presented) A compound according to claim 123, wherein each R^G is independently -H.

155. (Previously Presented) A compound according to claim 123, wherein each R^G is independently -H, unsubstituted C₁₋₇alkyl, substituted C₁₋₇alkyl, or silyl.

156. (Previously Presented) A compound according to claim 123, wherein each R^G is independently -H; unsubstituted C₁₋₄alkyl; C₁₋₄alkyl substituted with one or more groups selected from optionally substituted C₅₋₂₀aryl, C₁₋₇alkoxy, C₁₋₇alkylthio, and acyloxy; or -SiR^S₃, wherein each R^S is independently -H or C₁₋₄alkyl.


157. (Previously Presented) A compound according to claim 123, wherein each R^G is independently -H; -Me; -Et; -nPr; -iPr; -allyl; -nBu; -sBu; -iBu; -tBu; C₁₋₄alkyl substituted with one or more groups selected from optionally substituted phenyl, methoxy, methylthio, acetoxy, and benzoyloxy; -Si(Me)₃; -Si(Et)₃; -Si(iPr)₃; -Si(tBu)(CH₃)₂; or -Si(tBu)₃.

158. (Previously Presented) A compound according to claim 123, wherein each R^G is independently (1) t-butyl, (2) allyl, (3) tri-isopropylsilyl, (4) acetoxymethyl, (5) methoxymethyl, (6) methylthiomethyl, (7) p-methoxyphenylmethyl, (8) bis(o-nitrophenyl)methyl, (9) benzyl, or (10) diphenylmethyl.


159. (Previously Presented) A compound according to claim 123, wherein each R^G is independently (1) t-butyl, (2) allyl, or (3) tri-isopropylsilyl.

160. (Previously Presented) A compound according to claim 123, wherein each R^G is independently (1) allyl.


161. (Previously Presented) A compound selected from compounds of the following formula (P-1), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:



162. (Previously Presented) A compound selected from compounds of the following formula (P-2), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:



163. (Previously Presented) A compound selected from compounds of the following formula (P-3), and pharmaceutically acceptable salts, solvates, amides, and esters thereof:



164. (Previously Presented) A composition comprising a compound according to claim 123, and a pharmaceutically acceptable carrier.

165. (Previously Presented) A kit comprising:
- (a) a compound according to claim 123; and
 - (b) instructions for use.
166. (Previously Presented) A kit comprising:
- (a) a compound according to claim 123;
 - (b) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,
 - (c) instructions for use.
167. (Previously Presented) A kit comprising:
- (a) a compound according to claim 123;
 - (b) a nucleic acid encoding a carboxypeptidase enzyme; and,
 - (c) instructions for use.
168. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo*, comprising contacting the cell with an effective amount of a compound according to claim 123.~~

Claim 169. (Canceled)

170. (Currently Amended) A method of treatment of colon cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123.

171. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo*~~, comprising contacting the cell with a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

Claim 172. (Canceled)

173. (Currently Amended) A method of treatment of colon cancer comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 123, in the presence of a carboxypeptidase enzyme.

174. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these, *in vitro* or *in vivo*~~, comprising:

(i) contacting the cell with an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

Claim 175. (Canceled)

176. (Currently Amended) A method of treatment of colon cancer, comprising administering to a subject in need of treatment:

(i) an antibody or fragment thereof conjugated or fused to a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

177. (Currently Amended) A method of ~~(a) regulating proliferation of a cell; (b) inhibiting cell cycle progression of a cell; (c) promoting apoptosis of a cell; or (d) a combination of one or more of these~~, *in vitro* or *in vivo*, comprising:

(i) contacting the cell with a nucleic acid encoding a carboxypeptidase enzyme; and,

(ii) contacting the cell with a therapeutically-effective amount of a compound according to claim 123.

Claim 178. (Canceled)

179. (Currently Amended) A method of treatment of colon cancer, comprising administering to a subject in need of treatment:

- (i) a nucleic acid encoding a carboxypeptidase enzyme; and,
- (ii) a therapeutically-effective amount of a compound according to claim 123.